Last updated: 7 June 2024 at 4:06pm EST

Jeffrey S Bornstein Net Worth




The estimated Net Worth of Jeffrey S Bornstein is at least $5.73 Million dollars as of 26 April 2022. Jeffrey Bornstein owns over 5,000 units of AlloVir stock worth over $30,550 and over the last 11 years Jeffrey sold ALVR stock worth over $5,698,100.

Jeffrey Bornstein ALVR stock SEC Form 4 insiders trading

Jeffrey has made over 26 trades of the AlloVir stock since 2013, according to the Form 4 filled with the SEC. Most recently Jeffrey bought 5,000 units of ALVR stock worth $23,200 on 26 April 2022.

The largest trade Jeffrey's ever made was exercising 200,000 units of AlloVir stock on 27 July 2017 worth over $152,000. On average, Jeffrey trades about 19,508 units every 78 days since 2013. As of 26 April 2022 Jeffrey still owns at least 40,197 units of AlloVir stock.

You can see the complete history of Jeffrey Bornstein stock trades at the bottom of the page.



What's Jeffrey Bornstein's mailing address?

Jeffrey's mailing address filed with the SEC is C/O ALLOVIR, INC., 1100 WINTER STREET, WALTHAM, MA, 02451.

Insiders trading at AlloVir

Over the last 4 years, insiders at AlloVir have traded over $46,310,999 worth of AlloVir stock and bought 5,850,170 units worth $60,516,413 . The most active insiders traders include Sciences, Inc. Gilead, Group, Llc Green Jeremy Red..., and Ansbert Gadicke. On average, AlloVir executives and independent directors trade stock every 9 days with the average trade being worth of $40,307. The most recent stock trade was executed by Diana Brainard on 20 August 2024, trading 5,390 units of ALVR stock currently worth $3,989.



What does AlloVir do?

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.



What does AlloVir's logo look like?

AlloVir, Inc. logo

Complete history of Jeffrey Bornstein stock trades at GE Aerospace and AlloVir

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
26 Apr 2022 Jeffrey S Bornstein
Buy 5,000 $4.64 $23,200
26 Apr 2022
40,197
10 Feb 2022 Jeffrey S Bornstein
Buy 5,000 $8.87 $44,350
10 Feb 2022
35,197
18 Feb 2021 Jeffrey S Bornstein
Sale 20,583 $40.43 $832,171
18 Feb 2021
0
6 Nov 2017 Jeffrey S Bornstein
Senior Vice President
Option 7,400 $154.85 $1,145,890
6 Nov 2017
192,183
9 Sep 2017 Jeffrey S Bornstein
Senior Vice President
Option 5,400 $183.23 $989,442
9 Sep 2017
187,324
27 Jul 2017 Jeffrey S Bornstein
Senior Vice President
Option 200,000 $198.38 $39,676,000
27 Jul 2017
279,086
24 Jul 2017 Jeffrey S Bornstein
Senior Vice President
Option 20,000 $195.62 $3,912,400
24 Jul 2017
88,757
31 Jan 2017 Jeffrey S Bornstein
Senior Vice President
Buy 5,000 $29.63 $148,150
31 Jan 2017
68,757
31 Jan 2017 Jeffrey S Bornstein
Senior Vice President
Buy 5,000 $29.63 $148,150
31 Jan 2017
68,757
5 Nov 2016 Jeffrey S Bornstein
Senior Vice President
Option 7,400 $218.77 $1,618,898
5 Nov 2016
71,157
27 Jul 2016 Jeffrey S Bornstein
Senior Vice President
Option 6,250 $240.62 $1,503,875
27 Jul 2016
66,817
24 Jul 2016 Jeffrey S Bornstein
Senior Vice President
Option 20,000 $246.62 $4,932,400
24 Jul 2016
70,355
3 Feb 2016 Jeffrey S Bornstein
Senior Vice President
Sale 168,313 $28.91 $4,865,929
3 Feb 2016
50,355
3 Sep 2015 Jeffrey S Bornstein
Senior Vice President
Option 10,000 $188.54 $1,885,400
3 Sep 2015
118,870
28 Jul 2015 Jeffrey S Bornstein
Senior Vice President
Option 7,500 $200.77 $1,505,775
28 Jul 2015
112,520
24 Jul 2015 Jeffrey S Bornstein
Senior Vice President
Option 20,000 $198.08 $3,961,600
24 Jul 2015
114,750
3 Sep 2014 Jeffrey S Bornstein
Senior Vice President
Option 10,000 $199.62 $1,996,200
3 Sep 2014
99,615
29 Jul 2014 Jeffrey S Bornstein
Senior Vice President
Option 6,250 $195.77 $1,223,563
29 Jul 2014
92,655
12 Sep 2013 Jeffrey S Bornstein
Senior Vice President
Option 12,500 $183.46 $2,293,250
12 Sep 2013
92,487
9 Sep 2013 Jeffrey S Bornstein
Senior Vice President
Option 9,167 $179.92 $1,649,327
9 Sep 2013
84,447
3 Sep 2013 Jeffrey S Bornstein
Senior Vice President
Option 10,000 $177.38 $1,773,800
3 Sep 2013
80,145
27 Jul 2013 Jeffrey S Bornstein
Senior Vice President
Option 6,250 $189.62 $1,185,125
27 Jul 2013
73,188


AlloVir executives and stock owners

AlloVir executives and other stock owners filed with the SEC include: